Leiden, Netherlands, July 23, 2026
Azafaros announced the successful completion of patient enrollment in its Phase 3 NAVIGATE study evaluating nizubaglustat for the treatment of late-infantile and juvenile GM1/GM2 gangliosidoses, marking an important milestone in the development of a potential disease-modifying therapy for these devastating rare neurodegenerative lysosomal storage disorders. The registrational study recruited at least 75 patients across 25 clinical sites in 13 countries, with topline results expected in early 2028. The company stated that enrollment in the companion Phase 3 NAVIGATE trial evaluating nizubaglustat for Niemann-Pick type C (NPC) disease remains ongoing. Completion of recruitment brings the GM1/GM2 program one step closer to potential regulatory submissions for a condition where no approved disease-modifying treatments currently exist.
Phase 3 NAVIGATE Study Evaluates Long-Term Disease Modification
The NAVIGATE Phase 3 program consists of two global, multicenter, randomized, double-blind, placebo-controlled studies designed to evaluate the efficacy, safety, and tolerability of oral nizubaglustat in patients with GM1/GM2 gangliosidoses and Niemann-Pick type C disease. The completed GM1/GM2 study is comparing oral nizubaglustat with placebo over an 18-month treatment period, with investigators focusing on improvements in neurological function, slowing disease progression, and preserving functional abilities. Following completion of the blinded treatment period, all participants will have the opportunity to continue receiving nizubaglustat through an open-label extension study. According to the company, the ongoing NPC Phase 3 trial aims to enroll approximately 72 patients, supporting the broader clinical development of the investigational therapy across multiple lysosomal storage disorders involving neurological impairment.
Nizubaglustat Targets Rare Neurological Lysosomal Disorders
Nizubaglustat is an investigational orally administered, brain-penetrant small molecule azasugar developed with a dual mechanism of action designed to treat lysosomal storage disorders affecting the central nervous system. The therapy is being investigated for GM1 gangliosidosis, GM2 gangliosidosis (including Tay-Sachs and Sandhoff diseases), and Niemann-Pick type C disease, all of which are progressive disorders caused by abnormal lipid accumulation within nerve cells that leads to severe neurological decline and premature death. The investigational medicine has received multiple regulatory incentives, including Rare Pediatric Disease Designation, Orphan Drug Designation, Fast Track Designation, and Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA), as well as Orphan Medicinal Product Designation from the European Medicines Agency (EMA) and an Innovation Passport from the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Advertisement
Program Advances Toward Regulatory Readout
Completion of enrollment represents a major advancement in Azafaros’ strategy to develop disease-modifying therapies for patients living with rare genetic neurological diseases. Company leadership acknowledged the contributions of patients, caregivers, investigators, and advocacy organizations that supported recruitment across multiple international clinical sites. Investigators emphasized that the completed Phase 3 trial is expected to generate the robust clinical evidence needed to determine whether nizubaglustat can become the first approved treatment for patients with GM1 and GM2 gangliosidoses, conditions that currently lack effective disease-modifying therapies. With topline data anticipated in early 2028, continued enrollment in the companion NPC Phase 3 study, and multiple regulatory designations already in place, Azafaros continues to strengthen the clinical and regulatory pathway for nizubaglustat as a potential treatment for rare lysosomal storage disorders with severe neurological involvement.
Source: Azafaros press release
